中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
18期
1085-1088
,共4页
徐志远%程向东%杜义安%黄灵
徐誌遠%程嚮東%杜義安%黃靈
서지원%정향동%두의안%황령
胃癌%化疗耐药%上皮间质转化%肿瘤干细胞%5-Fu
胃癌%化療耐藥%上皮間質轉化%腫瘤榦細胞%5-Fu
위암%화료내약%상피간질전화%종류간세포%5-Fu
gastric cancer%chemoresistance%epithelial-mesenchymal transition%cancer stem cell%5-Fu
目的：观察体外化疗能否诱导胃癌细胞发生上皮间质转化（epithelial mesenchymal transition，EMT）。方法：使用5-Fu （30μg/mL）对胃癌细胞株SGC7901进行4个疗程的体外化疗，残余细胞继续培养，得到能稳定传代的细胞SGC7901/Fu。比较SGC7901及SGC7901/Fu在细胞形态、EMT标记物、化疗耐药性、侵袭能力、肿瘤干细胞特性等方面的差异。结果：与SGC7901比较，SGC7901/Fu呈间质细胞形态、上皮表型标记物表达下调、间质表型标记物表达上调。在SGC7901细胞及SGC7901/Fu细胞中，5-Fu的中效浓度（IC50）分别为（43.8±7.2）μg/mL及（64.6±5.5）μg/mL，穿过Transwell小室基底膜的细胞数分别为（51.4±8.7）个及（93.2±9.5）个，克隆形成率分别为5.2%±1.0%及13.2%±2.2%，CD44+/CD24-细胞亚群所占比例分别为4.13%±0.81%及7.97%±0.50%，两者间的差异均具有统计学意义（P<0.05）。结论：体外化疗后残余的胃癌细胞发生EMT，同时细胞侵袭能力增强、化疗耐药性升高，并获得了肿瘤干细胞特性。
目的：觀察體外化療能否誘導胃癌細胞髮生上皮間質轉化（epithelial mesenchymal transition，EMT）。方法：使用5-Fu （30μg/mL）對胃癌細胞株SGC7901進行4箇療程的體外化療，殘餘細胞繼續培養，得到能穩定傳代的細胞SGC7901/Fu。比較SGC7901及SGC7901/Fu在細胞形態、EMT標記物、化療耐藥性、侵襲能力、腫瘤榦細胞特性等方麵的差異。結果：與SGC7901比較，SGC7901/Fu呈間質細胞形態、上皮錶型標記物錶達下調、間質錶型標記物錶達上調。在SGC7901細胞及SGC7901/Fu細胞中，5-Fu的中效濃度（IC50）分彆為（43.8±7.2）μg/mL及（64.6±5.5）μg/mL，穿過Transwell小室基底膜的細胞數分彆為（51.4±8.7）箇及（93.2±9.5）箇，剋隆形成率分彆為5.2%±1.0%及13.2%±2.2%，CD44+/CD24-細胞亞群所佔比例分彆為4.13%±0.81%及7.97%±0.50%，兩者間的差異均具有統計學意義（P<0.05）。結論：體外化療後殘餘的胃癌細胞髮生EMT，同時細胞侵襲能力增彊、化療耐藥性升高，併穫得瞭腫瘤榦細胞特性。
목적：관찰체외화료능부유도위암세포발생상피간질전화（epithelial mesenchymal transition，EMT）。방법：사용5-Fu （30μg/mL）대위암세포주SGC7901진행4개료정적체외화료，잔여세포계속배양，득도능은정전대적세포SGC7901/Fu。비교SGC7901급SGC7901/Fu재세포형태、EMT표기물、화료내약성、침습능력、종류간세포특성등방면적차이。결과：여SGC7901비교，SGC7901/Fu정간질세포형태、상피표형표기물표체하조、간질표형표기물표체상조。재SGC7901세포급SGC7901/Fu세포중，5-Fu적중효농도（IC50）분별위（43.8±7.2）μg/mL급（64.6±5.5）μg/mL，천과Transwell소실기저막적세포수분별위（51.4±8.7）개급（93.2±9.5）개，극륭형성솔분별위5.2%±1.0%급13.2%±2.2%，CD44+/CD24-세포아군소점비례분별위4.13%±0.81%급7.97%±0.50%，량자간적차이균구유통계학의의（P<0.05）。결론：체외화료후잔여적위암세포발생EMT，동시세포침습능력증강、화료내약성승고，병획득료종류간세포특성。
Objective:To investigate if in vitro chemotherapy can induce the EMT progress in gastric cancer (GC) cells. Method:The GC cell line, SGC7901, was treated using 5-Fu at a concentration of 30 μg/mL. The residual cells after four cycles of 5-Fu therapy were named as SGC7901/Fu. The morphological changes and malignant biological features, including the invasiveness and clone formation ability and the characteristics of cancer stem cell and biomarkers of EMT between SGC7901 and SGC7901/Fu, were compared. Results:The SGC7901/Fu cells displayed a mesenchymal appearance, decreased the expression of epithelial markers, and increased the expression of mesenchymal markers. The 50% inhibitory concentrations in the SGC7901/Fu and SGC7901 cells were (43.8 ± 7.2) and (64.6 ± 5.5)μg/mL, respectively. The number of cells that migrated through the basement-membrane of the Transwell chamber was 51.4 ± 8.7 and 93.2 ± 9.5, respectively. The rate of clone formation was 5.2%± 1.0%and 13.2%± 2.2%, respectively. The portions of the CD44+/CD24-cells were 4.13%±0.81%and 7.97%±0.50%, respectively. All differences were statistically significant (P<0.05). Conclusion:The residual GC cells underwent EMT progress after 5-Fu treatment, with increased chemoresistance and ability of invasiveness and acquired the property of cancer stem cells.
